Evidence mapPaperPMID 42582570Full record

ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2026

ESR1 fusions in breast cancer: functions, mechanisms and therapeutic opportunities.

Xuxu Gou, Zoya Farooqui, Charles E Foulds

Abstract readReview
In one paragraph

Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xuxu Gou *Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0003-2318-778X
Zoya Farooqui *Cancer and Cell Biology Graduate Program, Baylor College of Medicine, Houston, TX, USA.ORCID https://orcid.org/0009-0006-9305-6784
Charles E FouldsLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.ORCID https://orcid.org/0000-0003-4908-1473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 70% of all breast cancers are driven by estrogen receptor-alpha (ERα) that binds the predominant circulating female estrogen, 17ꞵ-estradiol (E2). Because of this, drugs collectively termed "endocrine therapy (ET)" that either suppress E2 level or inhibit the activity of ERα have been used as first-line therapy. While initially effective, resistance to ET drugs occurs with subsequent lethal metastasis. The most common genetic alterations are point mutations in the

Indexed as

breast cancerendocrine therapy (ET)ESR1 gene fusionEstrogen receptor (ER)

Identifiers

PMID42582570
PMCPMC13458063

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.